CY1121601T1 - Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα - Google Patents
Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεαInfo
- Publication number
- CY1121601T1 CY1121601T1 CY20191100250T CY191100250T CY1121601T1 CY 1121601 T1 CY1121601 T1 CY 1121601T1 CY 20191100250 T CY20191100250 T CY 20191100250T CY 191100250 T CY191100250 T CY 191100250T CY 1121601 T1 CY1121601 T1 CY 1121601T1
- Authority
- CY
- Cyprus
- Prior art keywords
- receptor
- compounds
- muscarine
- diamide compounds
- competitive activity
- Prior art date
Links
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title abstract 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 title 1
- 230000002860 competitive effect Effects 0.000 title 1
- 150000001470 diamides Chemical class 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 239000000168 bronchodilator agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Η εφεύρεση αυτή αναφέρεται σε μια ένωση του τύπου I: ή ένα φαρμακευτικώς αποδεκτό άλας αυτής. Τέτοιες ενώσεις διαθέτουν δραστικότητες τόσο ανταγωνιστή μουσκαρινικού υποδοχέα όσο και αγωνιστή β2 αδρενεργικού υποδοχέα. Η εφεύρεση αναφέρεται επίσης σε φαρμακευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις, διαδικασίες και ενδιάμεσα για την παρασκευή τέτοιων ενώσεων, και μεθόδους χρήσης τέτοιων ενώσεων ως βρογχοδιασταλτικών παραγόντων για τη θεραπευτική αγωγή πνευμονικών διαταραχών.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17203909P | 2009-04-23 | 2009-04-23 | |
EP13151470.5A EP2599778B1 (en) | 2009-04-23 | 2010-04-16 | Diamide Compounds having Muscarinic Receptor Antagonist and Beta 2 Adrenergic Receptor Agonist Activity |
PCT/US2010/031356 WO2010123766A1 (en) | 2009-04-23 | 2010-04-16 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY |
EP10715058A EP2421849B1 (en) | 2009-04-23 | 2010-04-16 | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121601T1 true CY1121601T1 (el) | 2020-05-29 |
Family
ID=42272140
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100498T CY1119008T1 (el) | 2009-04-23 | 2017-05-09 | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα |
CY20191100250T CY1121601T1 (el) | 2009-04-23 | 2019-02-28 | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100498T CY1119008T1 (el) | 2009-04-23 | 2017-05-09 | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα |
Country Status (32)
Country | Link |
---|---|
US (14) | US8138345B2 (el) |
EP (3) | EP2421849B1 (el) |
JP (3) | JP5671006B2 (el) |
KR (1) | KR101769061B1 (el) |
CN (2) | CN103936716B (el) |
AR (1) | AR076412A1 (el) |
AU (1) | AU2010239522B2 (el) |
BR (1) | BRPI1014877B8 (el) |
CA (1) | CA2758505C (el) |
CL (1) | CL2011002637A1 (el) |
CO (1) | CO6440584A2 (el) |
CY (2) | CY1119008T1 (el) |
DK (3) | DK2421849T3 (el) |
ES (3) | ES2635358T3 (el) |
HK (1) | HK1165799A1 (el) |
HR (3) | HRP20130468T1 (el) |
HU (2) | HUE042975T2 (el) |
IL (1) | IL215554A (el) |
LT (2) | LT2599778T (el) |
MX (1) | MX2011011156A (el) |
MY (1) | MY158339A (el) |
NZ (1) | NZ595850A (el) |
PL (3) | PL2421849T3 (el) |
PT (3) | PT2421849E (el) |
RU (2) | RU2676686C2 (el) |
SG (1) | SG175330A1 (el) |
SI (3) | SI3210981T1 (el) |
SM (1) | SMT201300060B (el) |
TR (1) | TR201903556T4 (el) |
TW (2) | TWI570115B (el) |
WO (1) | WO2010123766A1 (el) |
ZA (1) | ZA201107743B (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2758505C (en) | 2009-04-23 | 2017-03-07 | Theravance, Inc. | Diamide compounds having muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activity |
ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
AR083115A1 (es) * | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
HUE027000T2 (en) | 2011-06-10 | 2016-08-29 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
CA2838777C (en) | 2011-06-10 | 2019-04-30 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
LT3345904T (lt) | 2012-12-06 | 2020-09-25 | Chiesi Farmaceutici S.P.A. | Junginiai, pasižymintys muskarininių receptorių atžvilgiu antagonistinių ir beta-2-adrenerginių receptorių atžvilgių antagonistiniu aktyvumu |
RU2661877C2 (ru) | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
CN105142673B8 (zh) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
CN104030933A (zh) * | 2014-05-16 | 2014-09-10 | 烟台恒迪克能源科技有限公司 | 一种β-异烷醇基氨基戊酸环己胺的合成方法 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物 |
WO2016155573A1 (zh) * | 2015-03-27 | 2016-10-06 | 四川海思科制药有限公司 | 一种杂环衍生物及其制备方法和在医药上的用途 |
TW201702225A (zh) * | 2015-05-14 | 2017-01-16 | Sichuan Haisco Pharmaceutical Co Ltd | 具有β2受體激動及M受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途 |
TW201704211A (zh) * | 2015-05-14 | 2017-02-01 | Sichuan Haisco Pharmaceutical Co Ltd | 具有β2受體激動及M受體拮抗活性的聯苯衍生物及其在醫藥上的用途 |
AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
EP3383867B1 (en) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
EP3406606A4 (en) * | 2016-01-22 | 2019-06-26 | Sichuan Haisco Pharmaceutical Co., Ltd. | HETEROCYCLIC NITROGEN AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHRAMACEUTICAL APPLICATION |
WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
CA3047023C (en) | 2016-12-14 | 2022-05-31 | Beijing Showby Pharmaceutical Co., Ltd. | Class of bifunctional compounds with quaternary ammonium salt structure |
WO2018211530A1 (en) | 2017-05-19 | 2018-11-22 | Council Of Scientific & Industrial Research | Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof |
US11484531B2 (en) | 2018-08-30 | 2022-11-01 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
AU783095B2 (en) * | 1999-12-07 | 2005-09-22 | Theravance Biopharma R&D Ip, Llc | Carbamate derivatives having muscarinic receptor antagonist activity |
UA73543C2 (uk) * | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
OA12394A (en) | 2000-08-05 | 2004-07-09 | Glaxo Group Ltd | 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent. |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
WO2003049518A1 (fr) * | 2001-12-04 | 2003-06-12 | Tokyo R & D Co., Ltd. | Alimentation de courant |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
CN101239971B (zh) * | 2003-02-14 | 2011-07-20 | 施万制药 | 联苯衍生物 |
DK1708992T3 (da) | 2004-01-22 | 2007-11-05 | Pfizer | Sulfonamidderivater til behandling af sygdomme |
WO2005080375A1 (en) | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
US7307076B2 (en) | 2004-05-13 | 2007-12-11 | Boehringer Ingelheim International Gmbh | Beta agonists for the treatment of respiratory diseases |
JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
AU2006337928B2 (en) | 2006-02-08 | 2012-12-20 | Fuji Oil Company, Limited | Edible products with low content of saturated and trans unsaturated fats |
GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
TW200811105A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
TW200811104A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
CA2730499A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2758505C (en) | 2009-04-23 | 2017-03-07 | Theravance, Inc. | Diamide compounds having muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activity |
-
2010
- 2010-04-16 CA CA2758505A patent/CA2758505C/en not_active Expired - Fee Related
- 2010-04-16 CN CN201410175377.0A patent/CN103936716B/zh not_active Expired - Fee Related
- 2010-04-16 CN CN201080017581.XA patent/CN102405218B/zh not_active Expired - Fee Related
- 2010-04-16 PL PL10715058T patent/PL2421849T3/pl unknown
- 2010-04-16 ES ES13151470.5T patent/ES2635358T3/es active Active
- 2010-04-16 WO PCT/US2010/031356 patent/WO2010123766A1/en active Application Filing
- 2010-04-16 HU HUE17164740A patent/HUE042975T2/hu unknown
- 2010-04-16 PL PL13151470T patent/PL2599778T3/pl unknown
- 2010-04-16 AU AU2010239522A patent/AU2010239522B2/en not_active Ceased
- 2010-04-16 PT PT107150583T patent/PT2421849E/pt unknown
- 2010-04-16 SG SG2011077765A patent/SG175330A1/en unknown
- 2010-04-16 RU RU2015101032A patent/RU2676686C2/ru active
- 2010-04-16 DK DK10715058.3T patent/DK2421849T3/da active
- 2010-04-16 NZ NZ595850A patent/NZ595850A/xx not_active IP Right Cessation
- 2010-04-16 TR TR2019/03556T patent/TR201903556T4/tr unknown
- 2010-04-16 MX MX2011011156A patent/MX2011011156A/es active IP Right Grant
- 2010-04-16 SI SI201031866T patent/SI3210981T1/sl unknown
- 2010-04-16 SI SI201030228T patent/SI2421849T1/sl unknown
- 2010-04-16 BR BRPI1014877A patent/BRPI1014877B8/pt not_active IP Right Cessation
- 2010-04-16 KR KR1020117027797A patent/KR101769061B1/ko active IP Right Grant
- 2010-04-16 RU RU2011147374/04A patent/RU2543716C2/ru active
- 2010-04-16 PL PL17164740T patent/PL3210981T3/pl unknown
- 2010-04-16 MY MYPI2011004779A patent/MY158339A/en unknown
- 2010-04-16 LT LTEP13151470.5T patent/LT2599778T/lt unknown
- 2010-04-16 EP EP10715058A patent/EP2421849B1/en active Active
- 2010-04-16 SI SI201031498T patent/SI2599778T1/sl unknown
- 2010-04-16 JP JP2012507275A patent/JP5671006B2/ja not_active Expired - Fee Related
- 2010-04-16 ES ES17164740T patent/ES2715965T3/es active Active
- 2010-04-16 US US12/761,532 patent/US8138345B2/en not_active Expired - Fee Related
- 2010-04-16 PT PT131514705T patent/PT2599778T/pt unknown
- 2010-04-16 DK DK17164740.7T patent/DK3210981T3/en active
- 2010-04-16 PT PT17164740T patent/PT3210981T/pt unknown
- 2010-04-16 LT LTEP17164740.7T patent/LT3210981T/lt unknown
- 2010-04-16 EP EP13151470.5A patent/EP2599778B1/en active Active
- 2010-04-16 DK DK13151470.5T patent/DK2599778T3/en active
- 2010-04-16 ES ES10715058T patent/ES2417339T3/es active Active
- 2010-04-16 HU HUE13151470A patent/HUE035049T2/en unknown
- 2010-04-16 EP EP17164740.7A patent/EP3210981B1/en active Active
- 2010-04-23 AR ARP100101379A patent/AR076412A1/es active IP Right Grant
- 2010-04-23 TW TW104129981A patent/TWI570115B/zh not_active IP Right Cessation
- 2010-04-23 TW TW099112926A patent/TWI513693B/zh not_active IP Right Cessation
-
2011
- 2011-10-05 IL IL215554A patent/IL215554A/en active IP Right Grant
- 2011-10-19 CO CO11139777A patent/CO6440584A2/es active IP Right Grant
- 2011-10-21 CL CL2011002637A patent/CL2011002637A1/es unknown
- 2011-10-21 ZA ZA2011/07743A patent/ZA201107743B/en unknown
-
2012
- 2012-02-08 US US13/369,109 patent/US8551978B2/en active Active
- 2012-07-03 HK HK12106476.6A patent/HK1165799A1/xx not_active IP Right Cessation
-
2013
- 2013-05-27 HR HRP20130468AT patent/HRP20130468T1/hr unknown
- 2013-06-07 SM SM201300060T patent/SMT201300060B/xx unknown
- 2013-08-12 US US13/964,484 patent/US8816088B2/en not_active Expired - Fee Related
-
2014
- 2014-07-10 US US14/327,853 patent/US9000173B2/en not_active Expired - Fee Related
- 2014-08-15 JP JP2014165381A patent/JP5965440B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-04 US US14/638,171 patent/US9394275B2/en active Active
- 2015-05-22 JP JP2015104157A patent/JP2015147807A/ja active Pending
-
2016
- 2016-06-13 US US15/180,165 patent/US9572802B2/en active Active
- 2016-12-15 US US15/379,673 patent/US9682957B2/en active Active
-
2017
- 2017-04-26 US US15/497,446 patent/US9771350B2/en active Active
- 2017-05-09 CY CY20171100498T patent/CY1119008T1/el unknown
- 2017-06-26 HR HRP20170960TT patent/HRP20170960T1/hr unknown
- 2017-08-18 US US15/680,323 patent/US9975875B2/en active Active
-
2018
- 2018-04-23 US US15/959,549 patent/US10138220B1/en not_active Expired - Fee Related
- 2018-10-15 US US16/159,829 patent/US10358433B2/en not_active Expired - Fee Related
-
2019
- 2019-02-28 CY CY20191100250T patent/CY1121601T1/el unknown
- 2019-03-04 HR HRP20190417TT patent/HRP20190417T1/hr unknown
- 2019-06-07 US US16/434,220 patent/US10590107B2/en not_active Expired - Fee Related
-
2020
- 2020-01-28 US US16/774,024 patent/US10836744B2/en active Active
- 2020-10-08 US US17/065,689 patent/US20210024493A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121601T1 (el) | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα | |
EA200701705A1 (ru) | Антагонисты рецепторы глюкагона, получение и терапевтическое применение | |
EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
EA201170473A1 (ru) | Морфинановые соединения | |
EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
CL2007003826A1 (es) | Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion. | |
EA201201541A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ | |
EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
DK1957484T3 (da) | Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
WO2012101065A3 (en) | Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors | |
MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
EA200800540A1 (ru) | Карбоксамидные производные в качестве антагонистов мускариновых рецепторов | |
ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
EA200702612A1 (ru) | Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт | |
EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
EA201001566A1 (ru) | Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний | |
MA32479B1 (fr) | Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques | |
UA107702C2 (en) | Novel benzamide derivatives | |
BRPI0906632A2 (pt) | Imidazolinil metil aril sulfonamidas | |
CY1114205T1 (el) | ΕΝΩΣΕΙΣ ΔΙΑΜΙΔΙΩΝ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΥΠΟΔΟΧΕΑ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΥΠΟΔΟΧΕΑ | |
TH134761B (th) | สารประกอบไดเอไมด์ที่มีแอนทาโกนิสท์แอคทิวิตีต่อหน่วยรับมัสคารินิคและ อโกนิสท์แอคทิวิตีต่อหน่วยรับ b2 อะดรีเนอจิค | |
BRPI0907495A2 (pt) | sulfonamidas de imidazolinilmetil arila |